{"nctId":"NCT01263132","briefTitle":"Neuropathic Pain Management","startDateStruct":{"date":"2008-02"},"conditions":["Diabetic Neuropathies","Polyneuropathies"],"count":104,"armGroups":[{"label":"F0434","type":"EXPERIMENTAL","interventionNames":["Drug: F0434"]},{"label":"Gabapentin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gabapentin"]}],"interventions":[{"name":"F0434","otherNames":["Gabapentin with thiamine and cobalamin"]},{"name":"Gabapentin","otherNames":["Gababion","Gavindo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects diagnosed with diabetes mellitus type 2\n* Subjects with a history of neuropathic pain in the last 3 Months\n* Men and women in reproductive age with a family planning method\n* Subjects aged between 18 to 70 years\n* Subjects with glycosylated haemoglobin (HbA1c) greater than 7% and less than 15%\n* Subjects that obtain a grade equal or greater than 4 in the visual analogue scale during the screening visit\n\nExclusion Criteria:\n\n* Subjects diagnosed as being pregnant or in state of lactation\n* Subjects with serum creatinine greater than 1.2 or creatinine depuration in 24 hour urine, less than 60mL/min\n* Subjects who are receiving treatment with anti-depressants, anti-epileptics, and are taking vitamin B1 and B12 for treatment of neuropathic diabetes\n* Subjects who are being pharmacologically treated for epilepsy\n* Subjects diagnosed with rheumatic and hepatic disease and diagnosed with neuropathy for other causes\n* Subjects with psychological and psychiatric alteration that hinders adequate collaboration in the study\n* Subjects with any orthopaedic alteration of any extremity\n* Subjects with peripheral artery disease\n* Subjects taking more than two neuropathic pain medicines\n* Subjects with history of alcohol, cocaine, marijuana or benzodiazepine substance abuse\n* Subjects with acid-peptic disease\n* Subjects with history of neoplasm of any type","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Neuropathic Pain Score at Visit 3 (Week 1)","description":"Neuropathic pain score included 10 pain descriptors (intensity, stinging, burning, dull pain, coldness, sensitivity, numbness, depth, superficial and unpleasant) quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable). Questionnaire generated a score in each of the relevant dimensions and a total score of 0-100. Higher score indicated a greater intensity of pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.00","spread":"17.39"},{"groupId":"OG001","value":"50.70","spread":"16.67"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire","description":"SF-36 is a standardized health survey consisting of 36 questions to measure functional health status. Summary scores are calculated using the following 8 dimensions: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is obtained by SF-36 algorithm and it is represented as an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). Higher scores are indicative of a better health status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.044","spread":"22.409"},{"groupId":"OG001","value":"56.507","spread":"19.523"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.779","spread":"20.882"},{"groupId":"OG001","value":"65.610","spread":"18.599"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.531","spread":"18.987"},{"groupId":"OG001","value":"74.370","spread":"15.595"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.058","spread":"18.102"},{"groupId":"OG001","value":"78.075","spread":"15.819"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.869","spread":"17.010"},{"groupId":"OG001","value":"82.331","spread":"15.793"}]}]}]},{"type":"PRIMARY","title":"Mean Neuropathic Pain Score at Visit 4 (Week 2)","description":"Neuropathic pain score included 10 pain descriptors (intensity, stinging, burning, dull pain, coldness, sensitivity, numbness, depth, superficial and unpleasant) quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable). Questionnaire generated a score in each of the relevant dimensions and a total score of 0-100. Higher score indicated a greater intensity of pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.24","spread":"16.21"},{"groupId":"OG001","value":"36.94","spread":"15.05"}]}]}]},{"type":"PRIMARY","title":"Mean Neuropathic Pain Score at Visit 5 (Week 3)","description":"Neuropathic pain score included 10 pain descriptors (intensity, stinging, burning, dull pain, coldness, sensitivity, numbness, depth, superficial and unpleasant) quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable). Questionnaire generated a score in each of the relevant dimensions and a total score of 0-100. Higher score indicated a greater intensity of pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.74","spread":"19.54"},{"groupId":"OG001","value":"24.86","spread":"13.52"}]}]}]},{"type":"PRIMARY","title":"Mean Neuropathic Pain Score at Visit 6 (Week 4)","description":"Neuropathic pain score included 10 pain descriptors (intensity, stinging, burning, dull pain, coldness, sensitivity, numbness, depth, superficial and unpleasant) quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable). Questionnaire generated a score in each of the relevant dimensions and a total score of 0-100. Higher score indicated a greater intensity of pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.08","spread":"18.54"},{"groupId":"OG001","value":"17.29","spread":"15.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":["Dizziness","Drowsiness","Headache","Hypoglycemia","Lower Limb Edema"]}}}